Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Campath 1H in Haploidentical Stem Cell Transplant
NCT00058825Phase 2Terminated
- Sponsor
- Baylor College of Medicine
- Start
- Aug 2000
- Primary completion
- Sep 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of alemtuzumab in hematologic malignancy, Fanconi anemia (FA), aplastic anemia, paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Baylor College of Medicine. Started Aug 2000; status: terminated.
02
Drugs
alemtuzumab
03
Conditions
hematologic malignancyFanconi anemia (FA)aplastic anemiaparoxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT00058825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00058825.